Medical AI Alliance
← Company Index
Pharma & CDMOKOSDAQ 3043601 approvals5 trials

S.Biomedics Co., Ltd.

Official website

S.Biomedics develops proprietary stem cell differentiation and culture platforms, and sells anti-aging products like fillers through its subsidiary S.Tepharm.

As of 2026-10-10, S.Biomedics Co., Ltd. has 1 Korean MFDS drug approval, 22 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2003, S.Biomedics listed on KOSDAQ in 2023 as a stem cell therapeutics venture. Its proprietary platform, built on cell culture and cell aggregate technology, technology for inducing differentiation into specific cells, safety-securing technology to separate undifferentiated and tumorigenic cells, and GMP-certified production facilities, supports development of embryonic stem cell therapies, while its subsidiary S.Tepharm, established in December 2016, manufactures and sells anti-aging aesthetic products such as fillers and fibroblast-culture cosmetics. It is also researching a tissue-regenerating filler combining fillers with cell therapy, and the global stem cell medicine market is projected to grow from USD 13.7 billion (about KRW 19.9 trillion) in 2022 at a 14.9% CAGR to USD 39.93 billion (about KRW 58.8 trillion) by 2030.

Products & technology

  • 필러
  • 섬유아세포배양액 화장품

Regulatory approvals

data.go.kr

1 Korean MFDS drug approvals · 2021

  • MFDS drugCureSkin Inj.Revoked2021-07-29
    Drug · Prescription · Approval202105645

Clinical trials

data.go.kr

5 MFDS clinical trial authorisations · 2019–2023 (Phase 1/2a 3 · Phase 1/2 1 · Phase 3 1)

  • Phase 1/2aA9-DPC2023-01-12

    1 trial site

  • Phase 1/2a동종지방유래 중간엽줄기세포 집합체(3D-A)2020-03-17

    1 trial site

  • Phase 1/2자가피부유래 섬유아세포 집합체(3D-F)2020-02-25

    3 trial sites

  • Phase 1/2aPSA-NCAM(+) NPC2019-11-28

    4 trial sites

  • Phase 3큐어스킨2019-10-18

    7 trial sites

R&D and key agreements

Source: DART corporate disclosure

배아줄기세포 치료제 · 연구개발(고유 플랫폼기술 기반) · Proprietary technology in cell culture, differentiation induction, and safety assurance, supported by GMP-certified production facilities

조직재생 필러 · 연구 진행 중 · Research combining fillers with cell therapy for tissue regeneration

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched
Show 12 more publications

Patents

KIPRIS · applicant-matched
Show 39 more patents

AI reads

MAA server logs · IP-verified
59
Times AI engines pulled S.Biomedics Co., Ltd.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

1
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

58
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

13
live 1
Last 7 days
53
live 1
Last 30 days
59
live 1
All time
  • OpenAIChatGPT-Userlive1
  • OpenAIOAI-SearchBot51
  • GoogleGoogleOther2
  • PerplexityPerplexityBot2
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for S.Biomedics Co., Ltd. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies in the same categoryPharma & CDMO

ILDONG HOLDINGS CO.,LTD100

Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.

Yuyu Pharma, Inc.100

Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.

IL DONG PHARMACEUTICAL CO., LTD.100

Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.

Medy-Tox Inc.99

Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.

GC Biopharma Corp.97

KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.

DAEWON PHARMACEUTICAL CO.,LTD85

KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.

SAMSUNG BIOLOGICS CO.,LTD.85

Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.

GENOLUTION INC.85

Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.

AHN-GOOK PHARMACEUTICAL Co., Ltd.85

Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.

CORESTEMCHEMON Inc.85

Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.

BIO-FD&C CO.,LTD.85

Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.

HANDOK Inc.85

KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition